# US 6,730,666 B1 · Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,666 B1
- Document ID: US6730666B1
- Status: Granted
- Kind: B1
- Application number: 09/831,305
- Filed: 2001-07-18
- Granted: 2004-05-04
- Earliest claimed: 1998-11-08
- Assignees: Yeda Research and Development Co. Ltd.; Technion Research & Development Foundation Limited
- Inventors: Avner Yayon; David Aviezer; Zeev Gross
- Web page: https://patentgrep.com/patent/US6730666B1

## CPC

- C07D 487/22: in which the condensed system contains four or more hetero rings
- A61K 31/409: having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555)
- A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Tertrapyrrolic macrocycles selected from 5,10,15,20-tetraaryl-porphyrins and 5,10,15-triaryl-corrloes, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, inhibit growth factor (e.g. bFGF, VEGF) receptor tyrosine kinase activity, and are useful for inhibition of cell proliferation mediated by growth factor receptor tyrosine kinase activity for example for inhibition of angiogenesis, or vascular smooth muscle cell proliferation in disorders including atherosclerosis, hyperthrophic heart failure and postsurfical restenosis, and of cell proliferation and migration in the treatment of primary tumors and metastasis. Some of the 5,10,15,20-tetraaryl-prophyrins are novel compounds.

## Claims

### Claim 1

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a 5,10,15-triaryl-corrole of the formula:
wherein Ar1, Ar2, and Ar3, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8)alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, and wherein at least two of said aryl radicals are positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said carboaryl radical is phenyl substituted by fluoro and optionally by tri-(C1-C8) alkylammonium or amino-(C1-C8) alkylamino.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, wherein one or two of said carboaryl radicals is pentafluorophenyl and/or 4-aminopropylamino-2,3,5,6-tetrafluorophenyl.

### Claim 4 (depends on 2)

The pharmaceutical composition according to claim 2, wherein one to three of said carboaryl radicals is 4-trimethylammoniophenyl or 4-trimethylammonio-2,3,5,6-tetrafluorophenyl.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein one to three of said heteroaryl radicals is N-(C1-C8 alkyl)-pyridylium.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein said radical is selected from the group consisting of 2-, 3- and 4-(N-methyl) pyridylium.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said mixed carboaryl-heteroaryl radical is 4-(N-methyl-2-pyridylium)-2,3,5,6-tetrafluorophenyl.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the 5,10,15-triaryl-corrole is the compound 5,10,15-tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylium)]-21H,23H-corrole triiodide.

### Claim 9

A method for inhibiting growth factor receptor tyrosine kinase activity in a patient in need thereof, which comprises administering to said patient a tetrapyrrolic macrocycle selected from the group consisting of:
(a) a 5,10,15,20-tetraaryl-porphyrin of the formula:
wherein Ar1, Ar2, Ar3, and Ar4, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8)alkylamino, and tri-(Cl-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, wherein at least two of said Ar1, Ar2, Ar3, and Ar4 aryl radicals are positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion, provided that at least two of said at least two positively charged Ar1, Ar2, Ar3, and Ar4 aryl radicals are selected from the group consisting of N-(C1-C8)alkyl-pyridylium, 4-tri(C1-C8)alkylammonium)-2,3,5,6-tetrafluorophenyl and 4-N-(C1-C8)alkyl-pyridylium)-2,3,5,6-tetrafluorophenyl and, when at least two of said positively charged Ar1, Ar2, Ar3, and Ar4 radicals are N-(C1-C8)alkyl-pyridylium, at least one of the remaining Ar1, Ar2, Ar3, and Ar4 is a non-positively charged aryl radical selected from the group consisting of pentafluorophenyl and 4-amino(C1-C8)alkylamino-2,3,5,6-tetrafluorophenyl; and
(b) 5,10,15-triaryl-corrole of the formula:
wherein Ar1, Ar2, and Ar3, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8)alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, and wherein at least two of said aryl radicals are positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion;
in an amount sufficient to inhibit growth factor receptor tyrosine kinase activity.

### Claim 10 (depends on 9)

A method according to claim 9 which comprises administration of a 5,10,15,20-tetraaryl-porphyrin of the formula:
wherein Ar1, Ar2, Ar3, and Ar4, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8)alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, wherein at least two of said Ar1, Ar2, Ar3, and Ar4 aryl radicals are positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion, provided that at least two of said at least two positively charged Ar1, Ar2, Ar3, and Ar4 aryl radicals are selected from the group consisting of N-(C1-C8)alkyl-pyridylium, 4-tri(C1-C8)alkylammonium)-2,3,5,6-tetrafluorophenyl and 4-N-(C1-C8)alkyl-pyridylium)-2,3,5,6-tetrafluorophenyl and, when at least two of said positively charged Ar1, Ar2, Ar3, and Ar4 radicals are N-(C1-C8)alkyl-pyridylium, at least one of the remaining Ar1, Ar2, Ar3, and Ar4 is a non-positively charged aryl radical selected from the group consisting of pentafluorophenyl and 4-amino(C1-C8)alkylamino-2,3,5,6-tetrafluorophenyl, in an amount sufficient to inhibit said growth factor receptor tyrosine kinase activity.

### Claim 11 (depends on 10)

The method according to claim 10, wherein one or two of said carboaryl radicals is pentafluorophenyl and/or 4-aminopropylamino-2,3,5,6-tetrafluorophenyl.

### Claim 12 (depends on 10)

The method according to claim 10, wherein said carboaryl radical is phenyl substituted by fluoro and optionally by tri-(C1-C8) alkylammonium.

### Claim 13 (depends on 11)

The method according to claim 11, wherein one to two of said carboaryl radicals is 4-trimethylammonio-2,3,5,6-tetrafluorophenyl.

### Claim 14 (depends on 10)

The method according to claim 10, wherein said mixed carboaryl-heteroaryl radical is 4-(N-methyl-2-pyridylium)-2,3,5,6-tetrafluorophenyl.

### Claim 15 (depends on 10)

The method according to claim 10, wherein said 5,10,15,20-tetraaryl-porphyrin compound is selected from the group consisting of the compounds herein designated P15, P16, P17, P18, P19 and P20, namely:
P15 5,10,15,20-tetrakis(2,3,5,6-tetrafluoro-4-trimethylammonio-phenyl)-21H, 23H-methyl-porphine tetra-trifluoromethylsulfonate
P16 5-pentafluorophenyl-10,15,20-tris(N-methyl-4-pyridylium)-21H, 23H-porphine triiodide
P17 5,15-bis(pentafluorophenyl)-10,20-bis(N-methyl-4-pyridylium)-21H, 23H-porphine diiodide
P18 5,10-bis(pentafluorophenyl)-15,20-bis(N-methyl-4-pyridylium)-21H, 23H-porphine diiodide
P19 5,10,15-tris(N-methyl-4-pyridylium)-20-(2,3,5,6-tetrafluoro-4-aminopropyl-amino-phenyl)-21H, 23H-porphine triiodide
P20 5,10,15,20-tetrakis[4-(N-methyl-2-pyridylium) 2,3,5,6-tetrafluoro-phenyl]-21H, 23H-porphine tetraiodide.

### Claim 16 (depends on 9)

A method according to claim 9 activity which comprises administration of a 5,10,15-triaryl-corrole of the formula:
wherein Ar1, Ar2, and Ar3, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8)alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, and wherein at least two of said aryl radicals are positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion, in an amount sufficient to inhibit said growth factor receptor tyrosine kinase activity.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said carboaryl radical is phenyl substituted by fluoro and optionally by tri-(C1-C8) alkylammonium or amino-(C1-C8) alkylamino.

### Claim 18 (depends on 16)

The method according to claim 16, wherein one or two of said carboaryl radicals is pentafluorophenyl and/or 4-aminopropylamino-2,3,5,6-tetrafluorophenyl.

### Claim 19 (depends on 17)

The method according to claim 17, wherein one to three of said carboaryl radicals is 4-trimethylammoniophenyl or 4-trimethylammonio-2,3,5,6-tetrafluorophenyl.

### Claim 20 (depends on 16)

The method according to claim 16, wherein said one to three of said heteroaryl radicals is N-(C1-C8alkyl)-pyridylium.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said radical is selected from the group consisting of 2-, 3- and 4-(N-methyl) pyridylium.

### Claim 22 (depends on 16)

The method according to claim 16, wherein said mixed carboaryl-heteroaryl radical is 4-(N-methyl-2-pyridylium)-2,3,5,6-tetrafluorophenyl.

### Claim 23 (depends on 16)

The method according to claim 16 wherein the 5,10,15-triaryl-corrole is 5,10,15-tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylium)]-21H,23H-corrole triiodide.

### Claim 24 (depends on 9)

The method according to claim 9, wherein said growth factor receptor tyrosine kinase is selected from the group consisting of fibroblast growth factor (FGF) receptor tyrosine kinase, epidermal growth factor (EGF) receptor tyrosine kinase, heparin-binding EGF-like growth factor (HB-EGF) receptor tyrosine kinase, platelet derived growth factor (PDGF) receptor tyrosine kinase, vascular endothelial growth factor (VEGF) receptor tyrosine kinase, nerve growth factor (VGF) receptor tyrosine kinase, hepatocyte growth factor (HGF) receptor tyrosine kinase, insulin receptor tyrosine kinase and insulin-like growth factor (IGF) receptor tyrosine kinase.

### Claim 25 (depends on 9)

The method according to claim 9, wherein said patient in need is one in need of: (i) inhibition of angiogenesis; (ii) inhibition of vascular smooth muscle cell proliferation in disorders selected from the group consisting of atherosclerosis, hyperthrophic heart failure and postsurgical restenosis; (iii) inhibition of cell proliferation and migration in the treatment of primary tumors and metastasis; (iv) treatment of nonmalignant tumors; (v) treatment of diabetic retinopathy, psoriasis, rheumatoid arthritis, retrolental fibroplasia, macular degeneration, hemangioma, arteriovenous malformation, hypertrophic scars, acne, scleroderma and autoimmune diseases; or (vi) treatment of bone and cartilage related disorders and inherited skeletal disorders selected from the group consisting of achondroplasia, dwarfism and craniosynostosis.

### Claim 26 (depends on 25)

The method according to claim 25, wherein said patient in need is one in need of inhibition of angiogenesis, and wherein said tetropyrrolic macrocycle is 5,10,15-tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylium]-21H,23H-corrole triiodide, administered in an amount sufficient to effect said inhibition.

### Claim 27 (depends on 25)

The method according to claim 25, wherein said patient in need is one in need of inhibition of vascular smooth muscle cell proliferation in postsurgical restenosis, and wherein said tetropyrrolic macrocycle is 5,10,15,20-tetrakis(N-methyl-4-pyridylium)-21H,23H-porphine tetra-p-tosylate or 5,10,15,20-tetrakis[4-(N-methyl-2-pyridylium) 2,3,5,6-tetrafluoro-phenyl]-21H,23H-porphine tetraiodide, administered in an amount sufficient to effect said inhibition.

### Claim 28 (depends on 25)

The method according to claim 25, wherein said patient in need is one in need of inhibition of cell proliferation and migration in the treatment of primary tumors and metastasis, and wherein said tetropyrrolic macrocycle is 5,10,15-tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylium)]-21H,23H-corrole triiodide, administered in an amount sufficient to effect said inhibition.

### Claim 29 (depends on 25)

The method according to claim 25, wherein said patient in need is one in need of inhibition of FGFR-3 tyrosine kinase activity and treatment of achondroplasia, and wherein said tetropyrrolic macrocycle is 5-pentafluorophenyl-10,15,20-tris(N-methyl-4-pyridylium)-21H,23H-porphine triiodide, administered in an amount sufficient to effect said inhibition.

### Claim 30

A method for inhibiting angiogenesis, comprising administering an inhibitor which is a tetrapyrrolic macrocycle selected from the group consisting of:
(a) a 5,10,15,20-tetraaryl-porphyrin of the formula:
wherein Ar1, Ar2, Ar3, and Ar4, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8)alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, wherein at least two of said Ar1, Ar2, Ar3, and Ar4 aryl radicals are positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion; and
(b) 5,10,15-triaryl-corrole of the formula:
wherein Ar1, Ar2, and Ar3, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8)alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, and wherein at least two of said Ar1, Ar2, Ar3 aryl radicals are positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion;
in an amount sufficient to inhibit angiogenesis.

### Claim 31

A method for prevention of restenosis after percutaneous transluminal coronary angioplasty, comprising administering an inhibitor which is a tetrapyrrolic macrocycle selected from the group consisting of:
(a) a 5,10,15,20-tetraaryl-porphyrin of the formula:
wherein Ar1, Ar2, Ar3, and Ar4, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, wherein at least two of said Ar1, Ar2, Ar3, and Ar4 aryl radicals are positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion; and
(b) 5,10,15-triaryl-corrole of the formula:
wherein Ar1, Ar2, and Ar3, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, and wherein at least two of said Ar1, Ar2, Ar3 aryl radicals are positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion;
in an amount sufficient to inhibit smooth muscle cell proliferation.

### Claim 32

A method for inhibition of vascular smooth muscle cell proliferation in disorders selected from the group consisting of atherosclerosis, hyperthrophic heart failure and postsurgical restenosis, comprising the administration of an inhibitor which is a tetrapyrrolic macrocycle selected from the group consisting of:
(a) a 5,10,15,20-tetraaryl-porphyrin of the formula:
wherein Ar1, Ar2, Ar3, and Ar4, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8)alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, wherein at least two of said Ar1, Ar2, Ar3, and Ar4 aryl radicals are positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion; and
(b) 5,10,15-triaryl-corrole of the formula:
in an amount sufficient to inhibit said vascular smooth muscle cell proliferation.

### Claim 33

A 5,10,15,20-tetraaryl-porphyrin of the formula:
wherein Ar1, Ar2, Ar3, and Ar4, the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, wherein said carboaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, and said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl substituted by one or more halogen atoms, and/or one or more C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylamino, amino-(C1-C8) alkylamino, and tri-(C1-C8) alkylammonium radicals, wherein at least two of said Ar1, Ar2, Ar3, and Ar4 aryl radicals are positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion, provided that at least two of said at least two positively charged Ar1, Ar2, Ar3, and Ar4 aryl radicals are selected from the group consisting of N-(C1-C8)alkyl-pyridylium, 4-tri(C1-C8)alkylammonium)-2,3,5,6-tetrafluorophenyl and 4-N-(C1-C8)alkyl-pyridylium)-2,3,5,6-tetrafluorophenyl and, when at least two of said positively charged Ar1, Ar2, Ar3, and Ar4 radicals are N-(C1-C8)alkyl-pyridylium, at least one of the remaining Ar1, Ar2, Ar3, and Ar4 is a non-positively charged aryl radical selected from pentafluorophenyl or 4-amino(C1-C8)alkylamino-2,3,5,6-tetrafluorophenyl.

### Claim 34 (depends on 33)

The porphyrin of claim 33 being selected from the group consisting of the compounds 5-pentafluorophenyl-10,15,20-tris(N-methyl-4-pyridylium)-21H, 23H-porphine triiodide [P16]; 5,15-bis(pentafluorophenyl)-10,20-bis(N-methyl-4-pyridylium)-21H, 23H-porphine diiodide [P17]; 5,10-bis (pentafluorophenyl)-15,20-bis(N-methyl-4-pyridylium)-21H, 23H-porphine diiodide [P18]; 5,10,15-tris(N-methyl-4-pyridylium)-20-(2,3,5,6-tetrafluoro-4-aminopropyl-amino-phenyl)-21H,23H-porphine triiodide [P19] and 5,10,15,20-tetrakis[4-(N-methyl-2-pyridylium)-2,3,5,6-tetrafluoro-phenyl]-21H, 23H-porphine tetraiodide [P20].
